Six prepubertal children with chronic renal failure (group 1), six prepubertal children with renal transplants (group 2), and six pubertal children with renal transplants (group 3) who were short (mean height SD score, -3-2, range -4-5 to -1-6) and growing poorly (mean (range) growth velocity (cm/year) over the year before treatment: group 1, 4-8 (3.5-5.8), group 2, 2-3 (0.9-4.7), and group 3, 3-2 (0.5-6.5)) were treated with recombinant human growth hormone 30 units/m2/week in daily doses for a median of 0-98 years (range 0.25-0.99). Mean (range) growth velocity over
Short stature is a serious problem for children with chronic renal disease. Intensive conservative management of chronic renal failure,l early transplantation,2 and the use of lower doses of steroids since the introduction of cyclosporin3 have improved the growth prognosis for most children. There are still some children, however, whose growth fails to respond to these measures.1 2 Recombinant human growth hormone (rhGH) increases the rate of growth of short normal children,4 and produced significant improvements in growth in five children with chronic renal failure treated for six months. 5 We have therefore assessed the effect of pharmacological doses of rhGH given for a period of a year to short children with renal disease.
Patients and methods Three groups of children (six in each group) were selected for treatment with rhGH. Group 1 were prepubertal children with chronic renal failure. Their mean age was 7-7 years (range 50-104), five were boys, and their diagnoses were infantile polycystic kidney disease (n=2), posterior urethral valve (n=l), and dysplastic kidneys (n=3). Group 2 were prepubertal children with renal transplants. Their mean age was 12-1 years (range 9-5-15-8), three were boys, and their diagnoses were dysplastic kidneys (n=1), cystinosis (n=2), focal segmental glomerulosclerosis (n=1), unspecified glomerulonephritis (n=1), and posterior urethral valve (n=l). Group 3 were pubertal patients with renal transplants. Their mean age was 15-6 years (range 14-1-18-3), four were boys, and their diagnoses were dysplastic kidneys (n=2), reflux nephropathy (n= 1), juvenile nephronophthisis (n= 1), posterior urethral valve (n=1), and neonatal cortical necrosis (n=1). The children all fulfilled the following criteria on entry to the study: they had all attended the clinic for at least 18 months and they were all short with height SD scores more than 2 SD below the mean (n=17) or height velocity SD scores more than 1 SD below the mean (n= 12). None had diabetes, uncontrolled bone disease, nephrotic syndrome, or abnormal liver or thyroid function tests. All the patients with transplants were receiving prednisolone on alternate days in the morning. The mean (range) doses (mg/mi2) were: group 2, 14-9 (101-17-6) and group 3, 110 (8-619-4) .
The study was approved by the hospital ethics committee, and informed consent was obtained from the parents. The children continued to attend the outpatient clinics as before.
PHYSICAL ASSESSMENT Height (measured by the same observer (GW) with a Harpenden stadiometer), weight, and puberty stage6 were assessed every three months. Bone age was assessed at the beginning and end of the year.7 Growth measurements were expressed as SD scores for chronological age and bone age,8 and as height velocity (cm/ year). Blood pressure was measured at each visit, and the systolic pressure was used for comparisons.
BIOCHEMICAL AND HAEMATOLOGICAL ASSESSMENT
Blood was taken at entry to the study and then every three months for estimations of the concentrations of urea, electrolytes, creatinine, calcium, phosphate, bilirubin, albumin, haemoglobin, fasting blood glucose and glycated haemoglobin, the white cell and platelet counts, and the activities of alkaline phosphatase and aspartate aminotransferase. Glomerular filtration rate (ml/min/173 m2) was calculated with the height/creatinine formula.9 Urine was collected on arrival at the morning clinic for measurement of the calcium:creatinine ratio. There was no significant change in the number of episodes of transplant dysfunction/child during the year before (1-7, 0-6) compared with during treatment with rhGH (1-5, 0-6).
The urinary calcium:creatinine ratio was over 0-7 mmol/mmol in three children before they started taking rhGH, and remained above this level in two children. It did not exceed this level in any other child.
64 -. . Treatment with rhGH produced significantly improved growth in our group of children with chronic renal failure (group 1), confirming the results of a small preliminary study.5 Our children were selected because they had the lowest height SD scores among children attending the chronic renal failure clinic, and were failing to show catch up growth despite theoretically optimum medical management. It was not possible to match them with controls because of the large number of variables (for example, diagnosis, age of onset of chronic renal failure, and severity of chronic renal failure). Such rates of growth have, however, never before been achieved by any other means and are of such magnitude that a controlled trial of the short term effects of rhGH on the growth of children with conservatively managed chronic renal failure has become unnecessary. How rhGH exerts its effect in patients with uraemia is unknown. It may be that supraphysiological doses of rhGH are necessary to overcome peripheral resistance to the effect of growth hormone. 14 This theory is supported by the rise in insulin like growth factor 1 concentration seen in our patients. It may be that rhGH stimulates food intake and protein anabolism, as an improvement in food utilisation has been noted in uraemic rats treated with rhGH. 156 The improved growth rate with unchanged energy and protein intake in our patients suggests that an increase in the efficiency of food utilisation had occured.
Treatment with rhGH also produced a significant increase in the rate of growth in prepubertal patients with transplants (group 2), although in this group the changes were less obvious. Catch up growth usually occurs in prepubertal children after transplantation, but steroids may interfere with the onset and progress of puberty and the pubertal growth spurt so that a decline in growth rate during the peripubertal years is common.2 17 This decline in growth rate is associated with depression of the spontaneous secretion of growth hormone as was seen in the patients in this study.2 The less obvious response to rhGH in this group was likely to be due to steroids. We could not find an association between the dose of steroid and the response to rhGH, or between the severity of suppression of spontaneous growth hormone secretion and response to rhGH, but this may be because of the small numbers in our study. A larger dose of rhGH might overcome the steroid effect and improve growth rates further.
Results for the pubertal patients with transplants (group 3) are less easy to interpret because of the possible confounding effect of the pubertal growth spurt. We have previously reported, however, that pubertal growth is depressed in patients taking steroids.2 The optimum management of this group of patients remains difficult. Compliance was also less certain in the adolescents; two patients definitely did not take their drugs regularly. Only one young child abandoned treatment because of fear of injections. All were offered topical local anaesthetic cream, but this was only used by one. One patient with chronic renal failure developed hypocalcaemia. This probably resulted from inadequate calcium intake from a diet restricted in dairy products in a rapidly growing child. Calcium depletion could lead to unrecognised bone disease, which may be easily missed as a rise in alkaline phosphatase activity is expected as a reflection of the increased rate of growth.
Finally, growth hormone is known to be a mitogen. 22 Children with renal transplants are more susceptible to tumour formation because of immunosuppression. Longer experience of the use of rhGH in this group of children is necessary before the risks of tumour formation can be determined.
In conclusion, rhGH is useful in improving the rate of growth of children with chronic renal failure but, in view of possible side effects, should only be considered in those who are below the third centile for height and have failed to show catch up growth when energy intake is adequate, electrolyte and acid base balances are normal, and bone disease is controlled. In these children, the benefits of improved growth may outweigh the risks of a deleterious effect on renal function. Poor growth in patients with renal transplants is usually the result of treatment with steroids, and the first approach should be to reduce the dose of steroids to a minimum. Few young children fail to show -catch up growth after transplantation, but those who continue to grow at a low velocity below the third centile on the smallest possible steroid-dose may benefit from rhGH. Older children whose rate of growth is decreasing in association with delayed puberty as a result of treatment with steroids should be kept under review for a year. If the rate of growth continues to decrease, rhGH may be offered. In all patients with transplants the potential side effects must be considered carefully with the patient and parents.
Long term consequences and the effect on final height are unknown.
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